Skip to content

Multi-center Study to Evaluate the Safety and Efficacy of Aesculap MonoMax® for Abdominal Wall Closure

A Historically-controlled Single-arm Multi-center Prospective Trial to Evaluate the Safety and Efficacy of Aesculap MonoMax® Suture Material for Abdominal Wall Closure After Primary Median Laparotomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00572507
Acronym
ISSAAC
Enrollment
150
Registered
2007-12-13
Start date
2007-12-31
Completion date
2009-07-31
Last updated
2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Median Laparotomy

Keywords

Absorbable Monofilament Suture Material, Safety and Efficacy, Abdominal Wall/ Fascia, Laparotomy

Brief summary

MonoMax will be used for a continuous all-layer (except skin) suture to close abdominal wall after midline incision. The primary objective of this trial is to demonstrate that the frequency of wound infection and the frequency of reoperation due to burst-abdomen after primary median laparotomy for elective surgical intervention are equal or lower than in the INSECT trial. The secondary objectives are to demonstrate that the length of postoperative hospital stay and the frequency of abdominal hernias 12 months after the surgery are equal or lower than in the INSECT trial. \[Knaebel HP et al., 2005\]

Interventions

DEVICEMonoMax®

Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy

Sponsors

Aesculap AG
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age equal or greater than 18 years * Expected survival time \> 12 months * Patient undergoing elective and primary median laparotomy * BMI \< 35 * Expected length of skin incision \> 15 cm

Exclusion criteria

* Peritonitis * Emergency surgery * Coagulopathy * Current immunosuppressive therapy (\> 40 mg of a Corticoid per day or Azathioprin) * Chemotherapy within 2 weeks before operation * Radiotherapy of the abdomen completed less than 8 weeks before operation

Design outcomes

Primary

MeasureTime frame
frequency of wound infection, frequency of reoperation due to burst-abdomen after primary median laparotomytill day of discharge

Secondary

MeasureTime frame
length of postoperative hospital stay after surgery and frequency of incisional hernias 12 months after the surgery and frequency of wound infections 30 days postoperativedifferent

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026